• Home  
  • ‘Europe cannot compete at yesterday’s speed’: Pharma industry wants reform, patients demand a say
'Europe cannot compete at yesterday’s speed': Pharma industry wants reform, patients demand a say
- Europe

‘Europe cannot compete at yesterday’s speed’: Pharma industry wants reform, patients demand a say

From clinical trials moving to China to growing concerns over medicine supply chains, Europe’s pharmaceutical sector is facing mounting pressure to become more competitive. The EU’s proposed Biotech Act aims to reverse the trend. But industry and patient groups disagree on the price of making Europe an innovation hub. The proposed European Biotech Act is

From clinical trials moving to China to growing concerns over medicine supply chains, Europe’s pharmaceutical sector is facing mounting pressure to become more competitive. The EU’s proposed Biotech Act aims to reverse the trend. But industry and patient groups disagree on the price of making Europe an innovation hub.

The proposed European Biotech Act is intended to strengthen Europe’s position in global pharmaceutical research and development, support innovation, and encourage companies to keep their investments in the EU. Yet a roundtable in the European Parliament revealed differing views on how far the EU should go to attract industry investment and who should benefit from the resulting incentives.

If we have all the active substances manufactured in China, what is the first step they will take in case of any conflict? They will stop it. And then we have no chance to bring medicines to European patients.
— David Kolář, President, AIFP

MEP Ondřej Krutílek (ECR/CZE) and the Czech Association of the Innovative Pharmaceutical Industry (AIFP) hosted the discussion. It brought together representatives of the pharmaceutical industry, the Czech Ministry of Health, and patient organisations.

You might be interested

For David Kolář, AIFP’s president, the legislation represents an important opportunity to reverse Europe’s declining competitiveness. “Since COVID, Europe has really realised that we need to take significant steps in the life sciences area because we are losing speed, power and investment compared with the US and Asia, especially China,” he said.

Previous EU initiatives had raised expectations. But Mr Kolář argued that they had not delivered the changes needed to make Europe more attractive to pharmaceutical companies.

MEP Ondřej Krutílek (ECR/CZE) argued that the EU must make better use of its single market and harmonise clinical trial procedures to strengthen Europe’s competitiveness in clinical research and improve patient access to innovative treatments.

He sees the Biotech Act as the last real opportunity to reverse the declining competitiveness of clinical research in Europe. The draft law addresses several interconnected aspects of the pharmaceutical sector rather than focusing on clinical research alone. Therefore, the potential benefits extend beyond drug development, he said, as pharmaceutical investment can also support manufacturing, services, and employment across Europe.

Losing ground to China

Alexandra Tamas co-leads the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) Biotech Advocacy Task Force and serves as a public affairs director at Novartis. She shared the concerns about Europe’s position in the global market.

We need to have a proper discussion at the table where we can be heard and listened to.
— Solène Jouan, Policy Officer, European Patients’ Forum

“The world is not waiting for Europe,” she said. “There are other regions that are really keen to attract biotechnological investments, and Europe cannot compete at yesterday’s speed.” According to the figures she cited, China increased its share of global clinical trials from 8 per cent in 2018 to 22 per cent today, while Europe’s relative share has been shrinking.

Alexandra Tamas, co-lead of EFPIA’s Biotech Advocacy Task Force and public affairs director at Novartis, argued that faster clinical trial approvals do not mean weaker scientific assessments, highlighting the FAST-EU pilot’s success in reducing approval timelines through better coordination and more efficient procedures.

For Ms Tamas, this is about more than research. Decisions on where companies conduct clinical trials can influence where they subsequently manufacture products, invest, and develop expertise. “What we do today will actually influence business decisions and companies’ decisions in the next 10, 20, 30 years,” she said.

Innovation needs stronger incentives

One of the central questions in the Biotech Act debate concerns how to make Europe a more attractive location for pharmaceutical research and development. To reward companies investing in Europe, the proposal looks at intellectual property. Specifically, it includes a 12-month extension of the supplementary protection certificate (SPC) for qualifying medicines.

SPCs extend the effective patent protection of medicines to compensate for time spent obtaining regulatory approval. The proposed additional protection would be linked to meeting certain criteria under the new framework.

Ms Tamas argued that maintaining the proposed extension would send an important signal to companies considering where to invest. “It’s important for the Biotech Act proposal, the 12-month SPC proposal, to be maintained in the final text,” she said.

There are other regions that are really keen to attract biotechnological investments, and Europe cannot compete at yesterday’s speed.
— Alexandra Tamas, Director of Public Affairs, Novartis

She acknowledged that healthcare budgets and their long-term sustainability were important concerns for member states. However, she argued, innovation and affordability should not be treated as opposing objectives.

Patients need a place at the table

Patient organisations disagree with the proposed extension. Solène Jouan of the European Patients’ Forum (EPF) questioned whether there was sufficient evidence that extending SPC protection would actually increase pharmaceutical investment or improve Europe’s competitiveness. “We are opposed to the extension of the SPC,” she said.

She argued that extending market exclusivity could exacerbate existing inequalities in access to medicines. That concern is particularly prominent in countries where healthcare systems already struggle with the cost of innovative treatments. She also noted that the Commission had not provided evidence demonstrating why an SPC extension was the appropriate instrument to achieve the objective.

Investment creates public value only if we are able to translate research into access for patients.
— Jana Hlaváčová, Head of the Health Technology Assessment Unit, Ministry of Health of the Czech Republic

Ms Jouan questioned whether the proposal adequately accounted for the potential impact of new technologies, including artificial intelligence, which could accelerate medicine development. For the EPF, incentives should be more clearly linked to public health objectives and measurable benefits for patients.

The organisation also wants patient representatives to have a meaningful role in the governance of strategic projects supported under the Biotech Act. “It’s not a tick-box exercise. We need to have a proper discussion at the table where we can be heard and listened to,” Ms Jouan said.

Manufacturing is also a question of security

Beyond attracting investment, speakers highlighted the strategic importance of maintaining pharmaceutical manufacturing capacity in Europe. Mr Kolář argued that the issue should be viewed through the lens of European security and resilience, rather than solely as an economic competitiveness question. If Europe remains dependent on other regions for the production of active pharmaceutical ingredients, geopolitical tensions could threaten the supply of medicines.

“If we have all the active substances manufactured in China, what is the first step they will take in case of any conflict? They will stop it. And then we have no chance to bring medicines to European patients,” he said. He argued that the pharmaceutical sector should be treated as a strategic industry, alongside defence and energy.

If we try to make it a robust legislation which will cover everything, it will make this holistic approach completely stuck.
— MEP Ondřej Krutílek (ECR/CZE)

Jana Hlaváčová, head of the Health Technology Assessment Unit at the Czech Ministry of Health, also supported strengthening Europe’s research and manufacturing capacity. She said the Czech Republic wanted research, development, and manufacturing to remain in Europe, with the benefits of investment distributed more widely across the bloc rather than concentrated in already established centres. “Investment creates public value only if we are able to translate research into access for patients,” she said.

Jana Hlaváčová, head of the Czech Ministry of Health’s Health Technology Assessment Unit
Jana Hlaváčová, head of the Czech Ministry of Health’s Health Technology Assessment Unit, argued that faster clinical trial approvals must be accompanied by investment in healthcare infrastructure and sufficient staffing to ensure regulatory reforms deliver results in practice.

Ms Hlaváčová also stressed that the Biotech Act should be considered as part of a wider life sciences framework. Clinical research, health technology assessment, medicine registration, reimbursement, and digital health infrastructure need to work together. She welcomed the broader approach being discussed under the Irish Presidency, arguing that the EU should avoid treating different stages of pharmaceutical development as separate policy issues.

A debate over how much Brussels should do

The question of how to strengthen Europe’s pharmaceutical sector also raised a familiar debate over the division of responsibilities between the EU and its member states. Mr Krutílek argued that Brussels should concentrate on areas where European-level action can make a genuine difference. He listed research, innovation, and the conditions needed to bring new treatments from laboratories to patients.

Member states, meanwhile, should retain responsibility for ensuring that medicines ultimately reach their populations. “That’s the task of the European Union, and the member states’ task is to get the final medicines to the patients,” he said.

He also warned against turning the Biotech Act into an overly broad legislative package covering issues that could be better addressed through other initiatives. The legislation should focus on challenges specific to the biotechnology sector, he argued. It should not become a vehicle for resolving every outstanding pharmaceutical policy question. “If we try to make it a robust legislation which will cover everything, it will make this holistic approach completely stuck,” the lawmaker said.

Mr Krutílek also expressed support for making the proposed rules more ambitious in areas such as clinical trial approvals. He stressed that the final legislation would need to be properly enforced.

Fellow Czech MEP Ondřej Knotek (PfE/CZE) similarly called for a pragmatic approach. “We must be a bit more bold when it comes to European cooperation and the Biotech Act,” he said. He added that the legislation should deliver benefits for both businesses and patients while respecting the autonomy of member states.

His priority was to pursue realistic improvements and reduce unnecessary administrative burdens. He warned against becoming caught up in lengthy negotiations that ultimately deliver little change.

The legislation is only the beginning

The success of the Biotech Act will depend on whether member states are prepared to implement it and invest in the capacity needed to make the new rules work, Ms Hlaváčová said. She stressed that better cooperation between national authorities, healthcare providers, and other stakeholders would be essential.

Ms Tamas also called for a broader approach to cooperation, arguing that member states should look beyond traditional divisions between different parts of the bloc. Within national governments, too, health, economy, and finance ministries do not always work closely enough together, she noted. “The objective and the aim should be in mind rather than the tool,” she said.

The roundtable brought together pharmaceutical industry representatives, policymakers and patient organisations to discuss the proposed Biotech Act.

Ms Jouan, meanwhile, warned that the focus on political negotiations and economic competitiveness should not push patient concerns into the background. She called for greater recognition of patient organisations in the decision-making process.

For Mr Krutílek, the final outcome should be legislation that is targeted, practical, and capable of delivering measurable results. “We need to focus on legislation which will work for the future,” he said.

The challenge for EU policymakers will be to reconcile competing priorities: attracting investment, strengthening Europe’s strategic autonomy, keeping healthcare systems sustainable, and ensuring that patients benefit from pharmaceutical innovation. The Biotech Act may provide some of the necessary tools. Ultimately, however, its success will depend on how policymakers design and implement them.

Source: euperspectives.eu

About Us

Toolq Media Is a Global News Platform Covering the Latest Developments and Breaking Stories from Around The World, Including World News, Business, Finance, Technology, Health, Politics, Science, Entertainment, Sports, and More.

Toolq

Toolq @2026. All Rights Reserved.